Nightingale Health to provide biomarker analysis for the world’s largest blood-based prospective cohort study in Latin America
Comprehensive biomarker profiles of Mexico City Prospective Study blood samples to be analyzed.Nightingale Health, the Finnish innovator of an internationally recognized blood biomarker technology for studying chronic diseases, will perform large-scale metabolic profiling of the Mexico City Prospective Study cohort by analyzing the biomarker profiles of blood samples from a cohort of 150,000 study participants. Contracted by the Nuffield Department of Population Health at the University of